DRRX - DURECT Corporation
| Previous Close | 1.3100 |
| Open | 1.3200 |
| Bid | 1.2900 x 2200 |
| Ask | 1.3000 x 2900 |
| Day's Range | 1.2700 - 1.3300 |
| 52 Week Range | 0.7500 - 2.5500 |
| Volume | 111,166 |
| Avg. Volume | 737,053 |
| Market Cap | 209.096M |
| Beta | 2.10 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0110 |
| Earnings Date | Oct 29, 2018 - Nov 2, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2.50 |
- Benzinga•14 days ago
FDA Decision Sends Pain Therapeutics Reeling
The FDA rejected Pain’s lead asset and said the drug’s negatives outweigh its positives. "This is a bizarre conclusion to reach, especially during a time of staggering human and economic toll created by opioid abuse and addiction," Pain Therapeutics CEO Remi Barbier said in a statement. Pain Therapeutics said it will redirect its resources to advance its Alzheimer’s assets.
- PR Newswire•14 days ago
DURECT's Licensee Pain Therapeutics Receives Complete Response Letter from FDA for REMOXY® ER (oxycodone) Extended-Release Capsules CII
CUPERTINO, Calif. , Aug. 6, 2018 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that its licensee, Pain Therapeutics (Nasdaq: PTIE) reported that it received a Complete Response Letter ...
- Thomson Reuters StreetEvents•19 days ago
Edited Transcript of DRRX earnings conference call or presentation 1-Aug-18 8:30pm GMT
Q2 2018 DURECT Corp Earnings Call
- Associated Press•19 days ago
Durect: 2Q Earnings Snapshot
On a per-share basis, the Cupertino, California-based company said it had a loss of 4 cents. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
- PR Newswire•19 days ago
DURECT Corporation Announces Second Quarter 2018 Financial Results and Provides Corporate Update
Live Webcast of Earnings Call Today at 4:30 p.m. Eastern Time CUPERTINO, Calif. , Aug. 1, 2018 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended ...
- Motley Fool•21 days ago
Why Durect Corporation Stock Is Spiking Today
Durect gets some much-needed cash after its partner Indivior received a positive nod for its schizophrenia drug.
- PR Newswire•21 days ago
DURECT Announces FDA Approval of Indivior's PERSERIS™ (risperidone) Extended-Release Injectable Suspension for the Treatment of Schizophrenia in Adults
Approval triggers $5 million milestone payment to DURECT and future earn-out payments based on U.S. net sales CUPERTINO, Calif. , July 30, 2018 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced ...
- PR Newswire•27 days ago
DURECT Corporation Invites You to Join its Second Quarter 2018 Earnings Conference Call
CUPERTINO, Calif., July 24, 2018 /PRNewswire/ -- In conjunction with DURECT Corporation's (DRRX) second quarter 2018 financial results press release, you are invited to listen to a conference call that will be broadcast live over the internet on Wednesday, August 1, 2018 at 4:30 pm Eastern Time (1:30 pm Pacific Time). A live audio webcast of the presentation will be available by accessing DURECT's homepage at www.durect.com and clicking "Investor Relations." If you are unable to participate during the live webcast, the call will be archived on DURECT's website under Audio Archive in the "Investor Relations" section.
- Benzinga•29 days ago
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings And IPOs
The upcoming week could see some action due to the presence of a host of catalytic events that include PDUFA dates and earnings releases. Here are are the ones a biotech investor should keep a tab on. ...
- ACCESSWIRE•last month
Complimentary Technical Snapshots on Teva Pharma Industries and Three More Drug Makers Stocks
Stock Research Monitor: DEPO, DRRX, and ENDP LONDON, UK / ACCESSWIRE / July 9, 2018 / If you want a free Stock Review on TEVA sign up now at www.wallstequities.com/registration . In today's pre-market ...
- Benzinga•2 months ago
A Look At Biotech In 2018 And The Biggest Catalysts Coming Up In The Second Half Of The Year
Biotech stocks carved out modest gains in the first half of 2018 and outperformed the broader market, although their gains paled before those of the tech-weighted Nasdaq Composite Index. From the fundamental ...
- Benzinga•2 months ago
Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates
Biotech stocks had a fairly decent run in June, with the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB ) advancing about 3.5 percent through June 22 compared to the S&P 500's 1.8-percent gain. ...
- Zacks•2 months ago
Pain, Durect Plunge as FDA Committee Votes Against Remoxy ER
Pain Therapeutics (PTIE) plunges as the FDA Advisory Committee votes against the approval of its lead candidate, Remoxy ER.
- Motley Fool•2 months ago
Here's Why Drug Developer DURECT Corporation Plunged Today
Remoxy is the gift that keeps on giving (and not in a good way).
- Benzinga•2 months ago
Benzinga's Daily Biotech Pulse: Pain Therapeutics Drops 70%, Neon To Begin Trading
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 26) AngioDynamics, Inc. (NASDAQ: ANGO ) Chembio Diagnostics Inc ...
- PR Newswire•2 months ago
Results of FDA Advisory Committee Meeting for REMOXY® ER
CUPERTINO, Calif. , June 26, 2018 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today reported that a joint meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety ...
- Benzinga•2 months ago
The Week Ahead: Senate Weighs Sprint-T-Mobile Merger, Nike Earnings And A Slew Of IPOs
Below is a list of notable corporate events for the week beginning June 25. Note, this list is not comprehensive and all dates are subject to change. All times are ET. Monday Notable Earnings Carnival ...
- GlobeNewswire•2 months ago
New Research Coverage Highlights Durect, Credit Suisse Group, Obsidian Energy, TransCanada, Golden Star Resources, and Loxo Oncology — Consolidated Revenues, Company Growth, and Expectations for 2018
NEW YORK, June 07, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Durect ...
- ACCESSWIRE•2 months ago
Free Daily Technical Summary Reports on Endo International and Three Other Healthcare Stocks
Stock Research Monitor: ZGNX, DEPO, and DRRX LONDON, UK / ACCESSWIRE / June 7, 2018 / If you want a free Stock Review on ENDP sign up now at www.wallstequities.com/registration . Ahead of today's trading ...
- ACCESSWIRE•3 months ago
DURECT Corporation Approaching PDUFA Dates and Analysts Review
NEW YORK, NY / ACCESSWIRE / June 4, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on DURECT Corporation (DRRX) a biopharmaceutical company actively developing new therapeutics based on its Epigenetic Regulator Program and proprietary drug delivery platforms. As of May 5, 2017, DURECT held over 55 issued U.S. patents and over 355 issued foreign patents (which include granted European patent rights that have been validated in various EU member states). In addition, they have over 35 pending U.S. patent applications and over 100 foreign applications pending in Europe, Australia, Japan, Canada, and other countries.
- PR Newswire•3 months ago
DURECT Announces Amendment to Licensing Agreement with Sandoz Related to POSIMIR® (SABER®-Bupivacaine)
DURECT received an upfront payment from Sandoz of $20 million at the time the agreement between the two companies became effective in June 2017 and was initially eligible for up to an additional $43 million in payments based on successful development and regulatory milestones (of which $30 million is feasible following the results of the PERSIST Phase 3 clinical trial), and up to an additional $230 million in sales-based milestones. Sandoz received exclusive commercialization rights for POSIMIR in the U.S. upon regulatory approval with sole funding responsibility for commercialization activities. Sandoz has agreed to pay DURECT a tiered double-digit royalty on product sales for a defined period. Pursuant to the amended agreement, DURECT is now eligible for up to $30 million in milestone payments based on NDA approval, and remains eligible for up to an additional $230 million in sales-based milestones. Each party, pursuant to the Amendment, is also permitted to develop or commercialize competing products. The Amendment also includes modifications to DURECT's development obligations and to both parties' termination provisions, including a right for DURECT to terminate for convenience prior to NDA approval.
- Simply Wall St.•3 months ago
Want To Invest In DURECT Corporation (NASDAQ:DRRX)? Here’s How It Performed Lately
For investors, increase in profitability and industry-beating performance can be essential considerations in an investment. Below, I will examine DURECT Corporation’s (NASDAQ:DRRX) track record on a high level, to giveRead More...
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of DRRX earnings conference call or presentation 2-May-18 8:30pm GMT
Q1 2018 DURECT Corp Earnings Call
- Associated Press•4 months ago
Durect: 1Q Earnings Snapshot
The Cupertino, California-based company said it had a loss of 5 cents per share. The specialty pharmaceutical company posted revenue of $3.5 million in the period. In the final minutes of trading on Wednesday, ...
